Physician profile
Michael G Crincoli
NPI 1497728372
$152,528.28
in general payments reported to CMS, 2019-2025
56 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Sports Medicine (Physical Medicine & Rehabilitation) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,558 · 2020: $874 · 2021: $21K · 2022: $41K · 2023: $53K · 2024: $18K · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $9,281 · Food and Beverage: $8,669 · Travel and Lodging: $5,402 · Honoraria: $4,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,162.50 |
| Consulting Fee | $9,281.25 |
| Food and Beverage | $8,668.87 |
| Travel and Lodging | $5,402.36 |
| Honoraria | $4,875.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,814.01 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Ipsen Biopharmaceuticals, INC | $42,071.44 | 2019-2025 | Dysport |
| Allergan, INC. | $21,448.13 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $892.81 | 2023-2025 | Iovera |
| Merz Pharmaceuticals, LLC | $844.55 | 2021-2025 | Xeomin |
| Averitas Pharma INC. | $645.59 | 2024-2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $528.63 | 2019-2024 | Ultomiris |
| Microtransponder, INC. | $462.01 | 2023-2025 | |
| Amgen INC. | $440.35 | 2019-2024 | Uplizna, Aimovig |
| Sunovion Pharmaceuticals INC. | $330.74 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $276.45 | 2019-2023 | |
| Lundbeck LLC | $260.76 | 2020-2025 | Vyepti |
| Biogen, INC. | $229.03 | 2020-2023 | Spinraza |
| Novartis Pharmaceuticals Corporation | $200.55 | 2019-2020 | |
| Pfizer INC. | $172.39 | 2023-2025 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Crincoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.